US Corporate Distress Financial Stress SEC Filings — July 16, 2026

Chapter 11 plan confirmed; all 35.2M common shares canceled with zero distribution, representing a 100% loss for equity holders. Prepetition lenders receiving 5.1M new shares and warrants, signaling a complete debt-for-equity wipeout

Received Nasdaq delisting notice for bid price <$1.00 for 31 consecutive days. Already used reverse split (1:30) in Oct 2025, making it ineligible for 180-day cure period. Trading likely suspended July 21 if hearing not requested by July 17

Non-compliant with three Nasdaq rules simultaneously (bid price, MVPHS, MVLS). Has 180 days until Jan 11, 2027 to cure, but triple non-compliance suggests structural issues beyond price

Received NYSE American compliance notice on July 15, 2026, resolving Oct 2025 deficiency. Positive signal of operational turnaround and ability to maintain exchange listing

Nasdaq filed Form 25 on July 10 to delist; deregistration under Section 12(b) effective in ~90 days. OTC ticker NOTVQ now the only trading venue for what is essentially worthless equity

Hearing request deadline is July 17, 2026 (next day). Failure to request by this date triggers immediate suspension at open on July 21. Extremely tight timeline for any rescue

Emerging growth company status provides no exemption from listing rules. Market cap and price metrics all failing simultaneously indicates fundamental business deterioration

Compliance resolution covers Sections 1003(a)(i) and (ii) of NYSE American Company Guide, related to stockholders' equity and continued losses. Removal of this overhang could attract new investors

Court-confirmed plan cancels all existing common shares with zero recovery. Shareholders who held through the process lose entire investment. Prepackaged plan suggests this outcome was foreseeable

Trading suspension could occur as soon as July 21 if hearing not requested by July 17. No compliance extension available due to prior reverse split. Stock likely to trade OTC with minimal liquidity

Simultaneous failure on bid price ($1.00), MVPHS ($15M), and MVLS ($50M) suggests deep structural issues. 180-day cure period provides time but no guarantee of recovery

Shares now trade OTC under NOTVQ with effectively zero equity value. OTC markets have lower disclosure requirements and wider spreads, trapping retail holders

Company already used its one permitted reverse split in Oct 2025 (1:30) but still cannot maintain $1.00 bid. This signals fundamental business weakness that a stock split cannot fix

Both MVPHS and MVLS failing suggests market capitalization has fallen significantly. Without revenue or profitability data in filing, the risk of further decline is elevated

While compliance is restored, the original deficiency (Oct 2025) related to stockholders' equity and losses. The company remains vulnerable to future non-compliance if financials deteriorate

Across all three distressed companies (Inotiv, Cycurion, TG-17), there is zero insider buying reported. This absence of management skin-in-the-game is a strong negative signal about recovery prospects

Resolved NYSE American deficiency after 9 months. If the company has improved its equity position and reduced losses, this could mark an inflection point. Monitor next quarterly filing for evidence of operational recovery

Company plans to request hearing by July 17 deadline, which would stay suspension pending final decision. If panel grants continued listing with conditions, stock could rebound from distressed levels

180-day compliance period extends to Jan 11, 2027. If company executes operational improvements or a strategic transaction, it could regain compliance. Monitor for reverse split announcement or business update

Prepetition lenders receiving 5.1M new shares and warrants. If the reorganized private company executes a successful turnaround, these new securities could have value, but public shareholders are excluded

The three distressed companies (Inotiv, Cycurion, TG-17) all face severe equity risk. Short sellers could target similar micro-cap companies with low bid prices and prior reverse splits that are approaching compliance deadlines

As the only positive filing in this digest, SRXH stands out as a potential safe haven within the distressed micro-cap space. Its compliance resolution could signal broader operational health

Three of four filings involve delisting or non-compliance, suggesting exchanges are strictly enforcing continued listing rules. Companies that have used reverse splits are particularly vulnerable as they lose cure period protections

Cycurion's situation exemplifies the risk of reverse stock splits as a temporary fix. After a 1:30 split in Oct 2025, the stock still cannot maintain $1.00, leaving no compliance options. This pattern is likely repeating across micro-cap universe

Inotiv's prepackaged bankruptcy confirms that equity holders in distressed small caps often receive nothing. The 35.2M shares canceled with zero distribution is a stark reminder of the risk of holding common equity in highly leveraged small companies

Across all three distressed filings, there is zero insider buying activity. This absence of management confidence is a powerful negative signal and suggests insiders see no near-term recovery path

SRx Health Solutions demonstrates that resolving exchange deficiencies can remove a significant overhang. Companies that successfully navigate compliance processes may see valuation re-rating as delisting risk is eliminated

July 17, 2026 is the deadline to request Nasdaq hearing. Failure results in suspension on July 21. Watch for 8-K filing confirming hearing request and any interim relief granted

Nasdaq Form 25 filed July 10; deregistration effective ~Oct 2026. Monitor for any trading activity in NOTVQ and potential SEC reporting obligations post-emergence

Compliance deadline is January 11, 2027. Watch for any 8-K filings regarding reverse stock split, business combination, or other compliance strategies

Following compliance resolution, next 10-Q will be critical to confirm financial improvement. Watch for evidence of reduced losses or improved stockholders' equity

Monitor other micro-cap companies with low bid prices and prior reverse splits. Companies that exhausted compliance periods in Q2 2026 may face imminent delisting notices

Court confirmation received July 14; plan effective date to be announced. Watch for emergence of reorganized private company and any subsequent transactions

If hearing is requested, Nasdaq panel decision timeline is typically 30-45 days. Any positive ruling could provide temporary relief and trading opportunity